Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to ...

The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.

Wegovy and other GLP-1 medications have become extremely popular over the past few years. Novo Nordisk (which makes both ...

Market multiples for Novo Nordisk are also attractive now, especially with a forward P/E for 2025 at 28.3x. Learn more about NVO stock here.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Elon Musk, the richest person alive and the co-head of President-elect Donald Trump’s new Department of Government Efficiency ...

Catalent (CTLT) stock rises on reports of imminent $16.5 billion sale to Novo Holdings with FTC approval and EU Commission ...

That’s according to the latest data from real-time ad trackers iSpot.TV. Their analysts found AbbVie’s immunology drug duo ...

A preliminary study on popular weight loss drugs finds participants shed more weight on Zepbound than on Novo Nordisk’s ...

Eli Lilly and Company announced earlier this week that its popular obesity drug, Zepbound (tirzepatide) outperformed rival ...

Novo Nordisk, the manufacturer of Ozempic and Wegovy, has petitioned the Food and Drug Administration (FDA) to add ...

In the fierce race to dominate the weight loss drug market, global pharmaceutical giant Eli Lilly announced on Wednesday that ...